These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32132421)

  • 61. Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.
    Polydorou S; Ross S; Coleman P; Duncan L; Roxas N; Thomas A; Mendoza S; Hansen H
    Psychiatr Serv; 2017 Mar; 68(3):295-298. PubMed ID: 27745534
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.
    Liebschutz JM; Crooks D; Herman D; Anderson B; Tsui J; Meshesha LZ; Dossabhoy S; Stein M
    JAMA Intern Med; 2014 Aug; 174(8):1369-76. PubMed ID: 25090173
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
    Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD
    Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.
    Wyse JJ; Eckhardt A; Waller D; Gordon AJ; Shull S; Lovejoy TI; Mackey K; Morasco BJ
    J Addict Med; 2024 May-Jun 01; 18(3):300-305. PubMed ID: 38498620
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 67. The Comprehensive Addiction and Recovery Act: Opioid Use Disorder and Midwifery Practice.
    Murphy J; Goodman D; Johnson MC; Terplan M
    Obstet Gynecol; 2018 Mar; 131(3):542-544. PubMed ID: 29420414
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Non-buprenorphine opioid utilization among patients using buprenorphine.
    Daubresse M; Saloner B; Pollack HA; Alexander GC
    Addiction; 2017 Jun; 112(6):1045-1053. PubMed ID: 28107580
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Two Different Buprenorphine Treatment Settings With Similar Retention Rates: Implications for Expanding Access to Treatment for Opioid Use Disorder.
    Tierney M; Melino K; Adeniji A; Shumway M; Allen IE; Waters CM
    J Am Psychiatr Nurses Assoc; 2019; 25(4):305-313. PubMed ID: 30295107
    [No Abstract]   [Full Text] [Related]  

  • 70. Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence.
    Wakeman SE; Chang Y; Regan S; Yu L; Flood J; Metlay J; Rigotti N
    J Addict Med; 2019; 13(4):253-257. PubMed ID: 30550392
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacological treatment of opioid use disorder in pregnancy.
    Rodriguez CE; Klie KA
    Semin Perinatol; 2019 Apr; 43(3):141-148. PubMed ID: 30755340
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder.
    Berry ARW; Finlayson TL; Mellis LM; Urada LA
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769591
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Commentary on Freelemyer et al. (2014): medication-assisted treatment in Africa-need is growing but response remains tepid.
    Obot IS
    Addiction; 2014 Jan; 109(1):33-4. PubMed ID: 24438111
    [No Abstract]   [Full Text] [Related]  

  • 74. Opiate dependence treatment with buprenorphine: one year's experience in a family practice residency setting.
    Colameco S; Armando J; Trotz C
    J Addict Dis; 2005; 24(2):25-32. PubMed ID: 15784521
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 78. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study.
    Meyer MC; Johnston AM; Crocker AM; Heil SH
    J Addict Med; 2015; 9(2):81-6. PubMed ID: 25622120
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.